After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...

“Abrupt” reductions in antidepressant treatment “ranging from 20 percent to 50 percent” Increases in psychotropic drug ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

WATERTOWN, Mass. - Neumora Therapeutics , Inc. (NASDAQ: NMRA) shares dropped 6.4% after the clinical-stage biopharmaceutical company announced changes to its ongoing depression drug trials and ...

Psilocybin-assisted psychotherapy significantly improved a range of psychiatric symptoms among people with cancer, according ...

Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality ...

There’s a new crew of characters in HBO’s hit series The White Lotus, but people are already obsessing over one in particular ...

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

The American Society of Anesthesiologists released new guidance on the safe use of ketamine for nonanesthesia purposes, such ...